NASDAQ:ALKS

Alkermes (ALKS) Stock Forecast, Price & News

$28.01

-0.15 (-0.53%)

(As of 09/29/2023 ET)

Compare

Today's Range: $27.80
▼
$28.31
50-Day Range: $27.17
▼
$31.79
52-Week Range: $21.75
▼
$33.71

Volume: 1.18 million shs
Average Volume: 1.32 million shs
Market Capitalization: $4.67 billion

P/E Ratio: 49.14
Dividend Yield: N/A
Price Target: $33.33

Alkermes MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 19.0% Upside
$33.33 Price Target
Short Interest: Bearish
5.83% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.17
Upright™ Environmental Score
News Sentiment: 1.01
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 56.38%
From $0.94 to $1.47 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

359th out of 971 stocks

Pharmaceutical Preparations Industry

152nd out of 457 stocks

2.3

Analyst's Opinion

Consensus Rating
Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $33.33, Alkermes has a forecasted upside of 19.0% from its current price of $28.01.
Amount of Analyst Coverage
Alkermes has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.83% of the outstanding shares of Alkermes have been sold short.
Short Interest Ratio / Days to Cover
Alkermes has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Alkermes has recently increased by 2.43%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alkermes does not currently pay a dividend.
Dividend Growth
Alkermes does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alkermes is -1.17.

2.8

News and Social Media Coverage

News Sentiment
Alkermes has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Alkermes this week, compared to 4 articles on an average week.
Search Interest
8 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alkermes insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.76% of the stock of Alkermes is held by insiders.
Percentage Held by Institutions
95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Alkermes are expected to grow by 56.38% in the coming year, from $0.94 to $1.47 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alkermes is 49.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.74.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alkermes is 49.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 84.98.
Price to Book Value per Share Ratio
Alkermes has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alkermes (NASDAQ:ALKS) Stock

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Price History

30 days | 90 days | 365 days | Advanced Chart

ALKS Stock News Headlines

September 29, 2023 | americanbankingnews.com

Aadi Bioscience (NASDAQ:AADI) & Alkermes (NASDAQ:ALKS) Critical Survey

September 15, 2023 | finance.yahoo.com

Alkermes (ALKS) Stock Moves -0.84%: What You Should Know

October 1, 2023 | Goldco (Ad)

Biden's Digital Dollar Nightmare

On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!

September 13, 2023 | realmoney.thestreet.com

For Potential Alkermes Buyers, There's a Key Price Level to Watch

September 11, 2023 | finanznachrichten.de

Alkermes plc: Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

September 11, 2023 | finance.yahoo.com

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

September 7, 2023 | uk.style.yahoo.com

Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average

September 7, 2023 | finance.yahoo.com

Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) Program

October 1, 2023 | Goldco (Ad)

Biden's Digital Dollar Nightmare

September 7, 2023 | finance.yahoo.com

Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program

September 6, 2023 | finance.yahoo.com

Here's Why Alkermes (ALKS) is a Strong Momentum Stock

August 31, 2023 | finance.yahoo.com

Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants(R) Program

August 31, 2023 | finanznachrichten.de

Alkermes plc: Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

August 31, 2023 | finance.yahoo.com

Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

August 30, 2023 | stocknews.com

3 Best Biotech Stocks for Growth in September

August 30, 2023 | msn.com

Alkermes to grant Teva license for generic Vivitrol, settles litigation

August 30, 2023 | finanznachrichten.de

Alkermes plc: Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

August 30, 2023 | finance.yahoo.com

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

August 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Alkermes (ALKS)

August 28, 2023 | markets.businessinsider.com

Alkermes Honors Women's Equality Day

August 25, 2023 | stocknews.com

3 Biotech Stocks to Buy This Month and Beyond

August 25, 2023 | msn.com

Alkermes falls as activist holder Sarissa Capital cuts stake

August 25, 2023 | finance.yahoo.com

Why Is Alkermes (ALKS) Down 9% Since Last Earnings Report?

August 25, 2023 | stocknews.com

Is Now the Time to Buy Into Moderna, Inc. (MRNA)?

August 25, 2023 | seekingalpha.com

Alkermes: A Complicated Story Right Now

August 24, 2023 | msn.com

Lybalvi: Weighing In Light, But Tipping Alkermes' Scales

August 12, 2023 | finance.yahoo.com

Alkermes- Targeting Narcolepsy and Bipolar Disorder

See More Headlines

Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Company Calendar

Last Earnings: 7/26/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ALKS
CUSIP: G0176710
CIK: 1520262
Web: www.alkermes.com
Phone: (531) 772-8000
Fax: 781-890-0524
Employees: 2,280
Year Founded: 1987

Price Target and Rating

Average Stock Price Forecast: $33.33
High Stock Price Forecast: $40.00
Low Stock Price Forecast: $28.00
Forecasted Upside/Downside: +19.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.57
Trailing P/E Ratio: 49.14
Forward P/E Ratio: 29.80
P/E Growth: N/A
Net Income: $-158,270,000.00
Net Margins: 7.04%
Pretax Margin: 7.03%
Return on Equity: 2.33%
Return on Assets: 1.27%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 2.87
Quick Ratio: 2.48

Sales & Book Value

Annual Sales: $1.11 billion
Price / Sales: 4.20
Cash Flow: $0.25 per share
Price / Cash Flow: 111.58
Book Value: $6.35 per share
Price / Book: 4.41

Miscellaneous

Outstanding Shares: 166,560,000
Free Float: 158,631,000
Market Cap: $4.67 billion
Optionable: Optionable
Beta: 0.60

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Richard F. Pops (Age 61)
Chairman & CEO
Comp: $2.3M

Mr. Iain Michael Brown (Age 54)
Sr. VP & CFO
Comp: $867.75k

Mr. Blair C. Jackson (Age 50)
Exec. VP & COO
Comp: $1.05M

Mr. David Joseph Gaffin (Age 51)
Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
Comp: $1.08M

Dr. Craig C. Hopkinson M.D. (Age 55)
Exec. VP of R&D and Chief Medical Officer
Comp: $1.12M

Dr. Floyd E. Bloom M.D. (Age 86)
Founder

Mr. Thomas Harvey
Chief Information Officer & Sr. VP of IT

Ms. Sandra Coombs
Sr. VP of Corp. Affairs & Investor Relations

Mr. Michael J. Landine (Age 69)
Sr. VP of Corp. Devel. & Chief Risk Officer

Mr. Stephen Schiavo
Sr. VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALKS Stock - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings or view top-rated stocks.
What is Alkermes' stock price forecast for 2023?: 6 brokers have issued 12 month price targets for Alkermes' stock. Their ALKS share price forecasts range from $28.00 to $40.00. On average, they predict the company's stock price to reach $33.33 in the next year. This suggests a possible upside of 19.0% from the stock's current price.
View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts.
How have ALKS shares performed in 2023?: Alkermes' stock was trading at $26.13 at the beginning of the year. Since then, ALKS shares have increased by 7.2% and is now trading at $28.01.
View the best growth stocks for 2023 here.
When is Alkermes' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ALKS earnings forecast.
How were Alkermes' earnings last quarter?: Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $0.38 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.10. The business earned $617.40 million during the quarter, compared to analysts' expectations of $572.57 million. Alkermes had a trailing twelve-month return on equity of 2.33% and a net margin of 7.04%.
What ETFs hold Alkermes' stock?: ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB).
What guidance has Alkermes issued on next quarter's earnings?: Alkermes issued an update on its FY23 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $1.34-$1.57 for the period, compared to the consensus estimate of $1.12. The company issued revenue guidance of $1.55-$1.68 billion, compared to the consensus revenue estimate of $1.48 billion.
What is Richard F. Pops' approval rating as Alkermes' CEO?: 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).
What is Alkermes' stock symbol?: Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How do I buy shares of Alkermes?: Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Alkermes' stock price today?: One share of ALKS stock can currently be purchased for approximately $28.01.
How much money does Alkermes make?: Alkermes (NASDAQ:ALKS) has a market capitalization of $4.67 billion and generates $1.11 billion in revenue each year. The company earns $-158,270,000.00 in net income (profit) each year or $0.57 on an earnings per share basis.
How many employees does Alkermes have?: The company employs 2,280 workers across the globe.
Does Alkermes have any subsidiaries?: The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
How can I contact Alkermes?: Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.

This page (NASDAQ:ALKS) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial